Is it working?
Assess therapeutic efficacy in vivo through quantitative PET biomarkers, enabling early assessment of biological response.
Is your candidate producing the expected treatment response?
Early quantitative biomarkers help determine whether a treatment is working before conventional endpoints become apparent.
The method
VIEW-RESPONSE quantifies therapeutic response by longitudinal in vivo PET imaging of validated biological biomarkers. A baseline scan establishes each animal's pre-treatment condition, while follow-up scans during treatment measure changes over time.
TheraPET4D® analyzes these longitudinal data to provide a quantitative evaluation of biological response, enabling direct comparison between baseline and post-treatment scans and supporting early assessment of drug efficacy.
The answers
Is your treatment effective?
Therapeutic response: Quantitative assessment of biological efficacy using validated PET biomarkers.
How does the disease evolve over time?
Longitudinal disease monitoring: Non-invasive evaluation of disease progression throughout treatment.
Is your treatment causing unintended effects in non-target tissues?
Safety assessment: Quantitative PET imaging detects early biological changes in non-target tissues, before conventional endpoints reveal them.
Preclinical Models & Species
We offer access to a broad range of mouse and rat models, including healthy animals, orthotopic and subcutaneous tumor models, inflammation models, and selected transgenic models of neurodegenerative disease. The choice of animal strain and disease model is tailored to the specific objectives of each study.
Tracers
Our validated PET biomarkers include:
[18F]FDG
In vivo biomarker of glucose metabolism. Common indications associated with altered glucose metabolism:
- Decreased uptake: neurodegeneration, cerebral ischemia / stroke, and metabolic disorders.
- Increased uptake: tumors, inflammatory and infectious processes, and epileptic foci.
[89Zr]Zr-anti-TNFα
In vivo biomarker of TNFα expression. Common indications associated with altered TNFα expression:
- Decreased signal: anti-TNF therapy, immunodeficiency, advanced sepsis, and some immunosuppressive cancers.
- Increased signal: rheumatoid arthritis, inflammatory bowel disease (Crohn's disease and ulcerative colitis), psoriasis, ankylosing spondylitis, early sepsis, obesity / type 2 diabetes, and non-alcoholic steatohepatitis (NASH).
Is our treatment reducing inflammation in arthritis?
A company developing a novel anti-inflammatory therapy needed to demonstrate an early biological response before conventional efficacy endpoints became apparent. Using [89Zr]Zr-anti-TNFα PET imaging, TNF-α expression was assessed at baseline and after treatment to quantify changes in inflammation in affected joints.
Study design
Baseline PET imaging
- Intravenous administration of [89Zr]Zr-anti-TNFα.
- PET/MRI acquisition 24 hours after tracer injection.
Treatment
- Administration of different doses of the investigational therapy in disease animal models.
- Vehicle administration in disease animal models.
Post-treatment PET imaging
- Repeat [89Zr]Zr-anti-TNFα administration after the treatment period.
- PET/MRI acquisition 24 hours after tracer injection.
TheraPET4D® quantitative analysis
- Quantification of [89Zr]Zr-anti-TNFα uptake in joints and relevant organs.
- Comparison of baseline and post-treatment scans.
- Quantitative comparison between treated and vehicle-control groups.
Outcome
TheraPET4D® demonstrated a significant, dose-dependent reduction in [89Zr]Zr-anti-TNFα uptake in inflamed joints of treated animals compared with baseline and vehicle controls, providing an early quantitative measure of therapeutic response and supporting progression of the drug candidate.
Results are typically delivered within 1 month, depending on study design and scope.
Ready to start your molecular PET imaging study?
Schedule a technical consultation with the MIBIOTRACE team.